Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done to determine if citalopram is safe and effective in the treatment of alcohol dependence. A second purpose is to evaluate whether alcohol dependent individuals who differ in a specific genetic marker respond differently to citalopram.

Citalopram is a drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of depression. It belongs to a category of medications called selective serotonin re-uptake inhibitors or SSRIs. The U.S. FDA has not approved citalopram for the treatment of alcohol dependence. Therefore, it is being used "off-label" in this study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cincinnati
• Collaborator: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
• Treatments: Citalopram; Dexetimide; Serotonin; Serotonin Uptake Inhibitors

Criteria

Inclusion Criteria:

• Outpatients with a diagnosis of DSM-IV alcohol dependence

• Not morbidly obese or underweight

• Express desire to quit or cut down on drinking for duration of trial

Exclusion Criteria:

• Clinically significant laboratory evidence of diseases

• Have active psychological disorders other than alcoholism